<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Amicus Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/amicus-therapeutics-inc</link>
<description>Latest news and press releases for Amicus Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Feb 2026 21:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/amicus-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68356fff78dffbe2df0f47e0.webp</url>
<title>Amicus Therapeutics Inc</title>
<link>https://6ix.com/company/amicus-therapeutics-inc</link>
</image>
<item>
<title>BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-1</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-full-year-2025-financial-results-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-full-year-2025-financial-results-and-corporate-updates</guid>
<pubDate>Fri, 20 Feb 2026 21:01:00 GMT</pubDate>
<description>2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year</description>
</item>
<item>
<title>BioMarin Announces Closing of Private Offering of Senior Notes</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-announces-closing-of-private-offering-of-senior-notes</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-announces-closing-of-private-offering-of-senior-notes</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%.</description>
</item>
<item>
<title>Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-presents-new-long-term-data-both-galafoldr-migalastat-and</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-presents-new-long-term-data-both-galafoldr-migalastat-and</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and</description>
</item>
<item>
<title>BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-announces-pricing-of-private-offering-of-senior-notes-and-completion-of-syndication-of-new-senior-secured-term-loan-facility</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-announces-pricing-of-private-offering-of-senior-notes-and-completion-of-syndication-of-new-senior-secured-term-loan-facility</guid>
<pubDate>Thu, 29 Jan 2026 21:05:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions.</description>
</item>
<item>
<title>BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-announces-proposed-private-offering-of-senior-notes-and-syndication-of-new-senior-secured-term-loan-facility</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-announces-proposed-private-offering-of-senior-notes-and-syndication-of-new-senior-secured-term-loan-facility</guid>
<pubDate>Mon, 26 Jan 2026 12:45:00 GMT</pubDate>
<description>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").</description>
</item>
<item>
<title>BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-to-acquire-amicus-therapeutics-for-dollar48-billion-expanding-position-as-a-leader-in-rare-diseases-accelerating-revenue-growth-and-strengthening-financial-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/biomarin-to-acquire-amicus-therapeutics-for-dollar48-billion-expanding-position-as-a-leader-in-rare-diseases-accelerating-revenue-growth-and-strengthening-financial-outlook</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two</description>
</item>
<item>
<title>DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/dmx-200-action3-phase-3-trial-completes-recruitment-1</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/dmx-200-action3-phase-3-trial-completes-recruitment-1</guid>
<pubDate>Mon, 15 Dec 2025 07:02:00 GMT</pubDate>
<description>Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announces that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) has now successfully completed the planned recruitment and dosing of the 286th adult patient[1].</description>
</item>
<item>
<title>Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-third-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-third-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and</description>
</item>
<item>
<title>Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-upcoming-investor-conferences-november-2025-2025-10-31</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-upcoming-investor-conferences-november-2025-2025-10-31</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming</description>
</item>
<item>
<title>Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announce-third-quarter-2025-financial-results-november-4-2025</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announce-third-quarter-2025-financial-results-november-4-2025</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live</description>
</item>
<item>
<title>New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/new-4-year-data-pombilitir-cipaglucosidase-alfa-atga-opfoldar-miglustat-presented</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/new-4-year-data-pombilitir-cipaglucosidase-alfa-atga-opfoldar-miglustat-presented</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® PRINCETON, N.J., Sept. 08, 2025 (GLOBE</description>
</item>
<item>
<title>Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-upcoming-investor-conferences-september-2025-2025-08-29</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-upcoming-investor-conferences-september-2025-2025-08-29</guid>
<pubDate>Fri, 29 Aug 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming</description>
</item>
<item>
<title>Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-second-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-second-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER</description>
</item>
<item>
<title>Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announce-second-quarter-2025-financial-results-july-31-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announce-second-quarter-2025-financial-results-july-31-2025-2025</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live</description>
</item>
<item>
<title>Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-approval-pombilitir-cipaglucosidase-alfa-opfoldar</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-approval-pombilitir-cipaglucosidase-alfa-opfoldar</guid>
<pubDate>Wed, 25 Jun 2025 04:00:00 GMT</pubDate>
<description>Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO,</description>
</item>
<item>
<title>New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/new-analysis-pombilitir-cipaglucosidase-alfa-atga-opfoldar-miglustat-published-muscle</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/new-analysis-pombilitir-cipaglucosidase-alfa-atga-opfoldar-miglustat-published-muscle</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the</description>
</item>
<item>
<title>Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-upcoming-investor-conferences-june-2025-2025-05-30</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-upcoming-investor-conferences-june-2025-2025-05-30</guid>
<pubDate>Fri, 30 May 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming</description>
</item>
<item>
<title>Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-bank-america-2025-health-care-conference-2025-05-07</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-present-bank-america-2025-health-care-conference-2025-05-07</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at</description>
</item>
<item>
<title>Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-first-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/amicus-therapeutics-inc/news/amicus-therapeutics-announces-first-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Thu, 01 May 2025 04:00:00 GMT</pubDate>
<description>1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney</description>
</item>
</channel>
</rss>